BUSINESS WIRE
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
Bioptigen, Inc. announced today that the company has been awarded the Frost & Sullivan 2008 North American Excellence in Research Award for its work in ophthalmic optical coherence tomography.
'Bioptigen is honored to receive this recognition from Frost & Sullivan for our developments in spectral domain optical coherence tomography (SDOCT). We are particularly proud of the dedication and passion of the talented team responsible for our progress,' commented Eric Buckland, co-founder and Chief Executive Officer of Bioptigen, Inc.
Buckland explained that 'Bioptigen and our collaborators in academia and industry recognize the importance of our SDOCT implementation to pre-clinical research and development as well as to the clinical diagnosis of disease at its very earliest stages.' Dr. Joseph Izatt, Bioptigen' s co-founder and Chief Technology Officer, and Professor of Biomedical Engineering and Ophthalmology at Duke University, added, 'This recognition is validation of our vision for the current and future potential of SDOCT. Our emphasis looking forward is to extend the capabilities of our systems for functional imaging, and to search for new biomarkers of disease processes that will be uniquely accessible through the power of SDOCT.'
'Bioptigen's OCT imaging system is distinguished by demonstrably superior image quality, real time acquisition, processing and display, and a very high degree of flexibility,' notes Frost & Sullivan analyst Rasika Ramachandran. 'The company provides research grade equipment into markets as diverse as ophthalmology, oncology, orthopedics, and genomics, with flexibility in delivery optics and software. At the same time, their platform can be rapidly configured for ease of use in clinical diagnostics. With the unique performance and flexibility of their system, Bioptigen and its technology are poised for success,' said Ramachandran.
About The Award
Frost & Sullivan's Excellence in Research Award is bestowed upon a company that has carried out new 'disruptive' research; and has, in general, a strong commitment to research and development. This award recognizes a company's research and development program that has or is expected to bring significant contributions to the industry in terms of adoption, change, and competitive posture. The fruits of this research may already have or will potentially impact certain market sectors. The award also recognizes the company's overall research excellence as well as its commitment toward differentiating itself based on science-backed services or solutions.
About Bioptigen, Inc.
Bioptigen's pioneering in vivo optical imaging technology allows researchers and clinicians to see pathologies at their earliest stages. The sophisticated SDOCT hardware and software system enables real-time non invasive imaging of internal tissue microstructure at an unmatched level of precision and depth. Our system extends the application space to cover a wide range of human and animal subjects. These advances make it possible for researchers to open up new avenues of biological exploration and development, and clinicians to foster advances in disease detection and management. For more information visit www.bioptigen.com.
About Frost & Sullivan
Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit www.awards.frost.com.